Starting with a 12mg target and settling at 8mg because it provides sufficient results with better tolerability is a perfectly valid approach
(Learn More)
However, the Cre + Ex mice showed no difference in -cell mass from Cre Ex controls at baseline (1.65 0.18 mg)
Below is a timeline of confirmed developments and expected events in 2026 based on manufacturer announcements, FDA filings, and major media reporting
Ongoing studies are investigating the optimal combination of GLP-1 therapy with hormone replacement therapy, body composition monitoring technologies, and personalized dosing algorithms based on individual metabolic profiles
Richards P, Thornberry NA, Pinto S (2021) The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders